Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3679043 | 1.00 | MEN1 (0.40) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL923937 | 1.00 | MEN1 (0.40) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL9484160 | 1.00 | MEN1 (0.40) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL9483038 | 1.00 | MEN1 (0.40) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL9483893 | 1.00 | MEN1 (0.40) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL28269242 | 0.98 | MEN1 (0.39) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL459575 | 0.97 | — | — | |
| SCHEMBL28632214 | 0.95 | MEN1 (0.40) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL3430285 | 0.93 | MEN1 (0.39) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL926527 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10777809-B2 | Method for producing negative electrode active material for lithium ion secondary batteries | JNC CORPORATION (JP) | 2020-09-15 | — | — | US | disclosed |
| EP-3442060-B1 | METHOD FOR PRODUCING NEGATIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM ION SECONDARY BATTERIES | JNC CORP (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20190131621-A1 | METHOD FOR PRODUCING NEGATIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM ION SECONDARY BATTERIES | JNC CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3442060-A1 | METHOD FOR PRODUCING NEGATIVE ELECTRODE ACTIVE MATERIAL FOR LITHIUM ION SECONDARY BATTERIES | JNC Corporation (JP) | 2019-02-13 | — | — | EP | disclosed |
| US-9817312-B2 | Silicon-containing heat- or photo-curable composition | AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.À R.L. (LU) | 2017-11-14 | — | — | US | disclosed |
| US-20160266490-A1 | SILICON-CONTAINING HEAT- OR PHOTO-CURABLE COMPOSITION | AZ ELECTRONIC MATERIALS S.À R.L. (LU) | 2016-09-15 | — | — | US | disclosed |
| EP-3061792-A1 | SILICON-CONTAINING HEAT- OR PHOTO-CURABLE COMPOSITION | AZ Electronic Materials (Luxembourg) S.à.r.l. (LU) | 2016-08-31 | — | — | EP | disclosed |
| US-20140275463-A1 | ORGANOSILICON COMPOUND AND PRODUCTION PROCESS FOR THE SAME, AND POLYSILOXANE AND PRODUCTION PROCESS FOR THE SAME | CHISSO PETROCHEMICAL CORPORATION (JP) | 2014-09-18 | — | — | US | disclosed |
| EP-1548020-B1 | SILICON COMPOUND | JNC CORP (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1550664-B1 | SILICON COMPOUND | JNC CORP (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20050288468-A1 | Cyclic polysilsequisiloxanes substituted with a group containing a sulfonyl halide, especially ahalosulfonylphenyl group; living radical polymerization initiators, particularly for preparing acrylic polymers | JNC CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| US-20050250925-A1 | Silicon compound | JNC CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
| US-20050215807-A1 | Silsesquioxane derivative | JNC CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550664-A1 | SILICON COMPOUND | CHISSO CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1548020-A1 | SILICON COMPOUND | CHISSO CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20040249103-A1 | Silsesquioxane derivatives and process for production thereof | JNC CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040143081-A1 | Novel silicon compounds and process for preparation thereof | JNC CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| EP-1428795-A1 | SILSESQUIOXANE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040068074-A1 | Production process for silsesquioxane derivative having functional group and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-04-08 | — | — | US | disclosed |
| US-20040030084-A1 | Production process for silsesquioxane derivative and silsesquioxane derivative | JNC CORPORATION (JP) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275463-A1 | ORGANOSILICON COMPOUND AND PRODUCTION PROCESS FOR THE SAME, AND POLYSILOXANE AND PRODUCTION PROCESS FOR THE SAME | PIEZO1, PFAS, MCM6 | MEN1 2051/4885POLB 728/4885KMT2A 1925/4885 |
| US-20050215807-A1 | Silsesquioxane derivative | STS, SFXN1, SULT1A1 | MEN1 3228/4885POLB 2890/4885KMT2A 1372/4885 |
| US-20050288468-A1 | Cyclic polysilsequisiloxanes substituted with a group containing a sulfonyl halide, especially ahalosulfonylphenyl group; living radical polymerization initiators, particularly for preparing acrylic polymers | STS, SULT1A1, SRM | MEN1 4416/4885POLB 3056/4885KMT2A 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.